Genmab — Juni 2018
-
Jeg ser ikke CheckMate-039 have været på hold, men det tyder i stedet for på at det er andre kombinations-studier, som var på hold. Herunder Keytruda igen. https://www.onclive.com/web-exclusives/fda-lifts-holds-on-2-nivolumab-myeloma-trials
-
Dejligt at se AB, som største køber i dag - bliver spændende at se hvordan de handler ved luk
-
Jeg kan slet ikke finde CM-039, der beskrives som: CheckMate-039 is a study to establish the tolerability of nivolumab and the combination of nivolumab and daratumumab (Darzalex), with or without pomalidomide and dexamethasone, in patients with relapsed/refractory multiple myeloma.
-
På google får jeg dette: https://www.youtube.com/watch?v=JAlEDi2rugE
-
-
Det lyder bestemt ikke urealistisk. Kan ikke huske om det de lå som største nettokøber indtil tæt på luk, i mandags?
-
this is just weird and/or stupid
. New: "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Daratumumab or Erdafitinib in Japanese Participants With Advanced Solid Cancers" -
-
a the same time the ASCLEPIOS II MS trial is rectified again lol https://clinicaltrials.gov/ct2/history/NCT02792231?A=16&B=17&C=merged
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind